AlveoGene’s Post

Vice President of Avirmax Inc. will Chair Sessions at the 27th ASGCT 2024 Annual Conference in Baltimore NEWS PROVIDED BY Avirmax 29 Mar, 2024, 16:40 ET HAYWARD, Calif., March 29, 2024 /PRNewswire/ -- Li Ou, Ph.D., Vice President of Research at Avirmax Inc., will chair two scientific sessions at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024. ASGCT is the largest international society dedicated to understanding, development, and application of gene and cell therapy. These two sessions that Dr. Ou chairs will be: Continue Reading Dr. Li Ou of Avrimax pushes for fundamental scientific understanding of AAV vectors with session chairing at ASGCT'24 Session Title: A3 - AAV Vectors - Capsid Engineering Session 1 Date and Time: Wednesday, May 8, 2024, 3:45 PM Session Title: 2nd Annual 5-Minute Thesis Challenge Date and Time: Friday, May 10, 2024, 8:00 AM Dr. Li Ou is a current committee member of ASGCT and a well-established investigator in preclinical research in AAV gene therapy and gene editing. Dr. Ou joined Avirmax in July 2023 and has since been leading in expanding the Company's research programs in capsid engineering and in vivo programs. An avid advocator of unlocking the hidden potential of AAV, Dr. Ou is dedicated to the groundwork of translational development while spearheading institutional collaboration. Before joining Avirmax, Dr. Ou was an Assistant Professor at the University of Minnesota, where he spearheaded research on gene therapy for lysosomal diseases, resulting in two IND approvals from the FDA. On Feb 16th, he moderated the ASGCT Professional Development Café online webinar, featuring a talk on Utilizing AI in Gene & Cell Manufacturing. In addition to the scientific sessions, Avirmax will exhibit in booth #818 showcasing the latest AAV platform technologies. About Avirmax Inc. Avirmax Inc. is a San Francisco-based company specializing in developing rAAV-mediated therapeutics for ocular diseases using its AAV proprietary capsid engineering technologies and Sf9-based rAAV manufacturing platform. Since its inception, Avirmax has been dedicated to developing safe, effective, affordable, and accessible AAV gene therapy products for the unmet needs of patients. Visit us at avirmax.com for more information. Contact Please contact June Song, Associate Director of Operations Email: [email protected] Tel: +1-510-641-0201 Address 25503 Whitesell Street Hayward, CA 94545 USA SOURCE Avirmax Contact PR Newswire Products About My Services PR Newswire Distribution Helpline 888-776-0942

Join us this November for the Sydney International Conference, ‘Advancing Multi-Omics into the Clinic’—Australia, 18th-19th Nov 2024! 🌏✨ Over two days, experts from around the globe will discuss the latest innovations in proteomics, genomics, multi-omic data integration within cancer research, drug discovery, regulatory approvals, and commercialisation challenges. Key topics will include:  - Translating cancer signatures into clinical insights  - AI and machine learning for omics  - Multi-omic breakthroughs and drug discovery  - The future of precision medicine Don’t miss out! This will be a great opportunity to hear from top experts in multi-omics, network, and possibly establish new collaborative projects. Register here: https://lnkd.in/dstS8Gyx NSW Health, Thermo Fisher Scientific, Australian Genome Research Facility (AGRF), University of Sydney, Children's Medical Research Institute. #ClinicalResearch, #AdvancingMultiOmicsintotheClinc, #proteomics, #CancerResearch, #MultiOmics, #Drugdiscovery

Avirmax Biopharma Inc. to Present at the 2024 ARVO Annual Meeting in Seattle NEWS PROVIDED BY Avirmax 01 Apr, 2024, 15:02 ET HAYWARD, Calif., April 1, 2024 /PRNewswire/ -- Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024. ARVO is the largest international society dedicated to ophthalmology and vision-related topics. Continue Reading Dr. Shengjiang Liu, Ph.D. Chief Executive and Scientific Officer, is invited to present "Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells", at the 2024 ARVO Symposium on "Developing gene therapy for glaucoma neuroprotection: Opportunities and challenges", May 9, 8 – 10 am. Avirmax Biopharma Is Unlocking A Great Potential of AAV-based Genetic Medicines for Millions of Patients' Vision In addition to the invited talk, there will be two more scientific presentations from Avirmax Biopharma and an exhibitor booth #1604 to showcase the latest progress and data package: Title: Novel AAV2 capsid expressing Aflibercept shows efficacy and sustainability in rabbit DL-AAA model Presenter: Sameera Peraramelli, Ph.D. Presentation Type: Oral Presentation Session: AMD: Translational studies Date and time: May 9, 2024 from 11:45 AM to 1:30 PM Title: Macular retina-targeting AAV capsid identified through multi-species screening in mice, rabbits, pigs, and monkeys Presenter: Shengjiang Liu, Ph.D. Presentation Type: Poster Session Session: Gene and cell therapies and other novel therapeutics I Date and time: May 8, 2024 from 2:15 PM to 4:00 PM These presentations will focus on Avirmax Biopharma's lead candidate ABI-110 for wet AMD and PCV using a proprietary novel capsid AAV2.N54. AAV2.N54 was developed through capsid engineering and showed significantly improved tropism to the macular retina over wildtype serotypes and AAV2.7m8 in mice, rabbits, pigs, and non-human primates. Avirmax Biopharma has completed cGMP manufacturing of ABI-110 using VSaf™ rAAV Production Platform with Sf-rhabdovirus free Sf9 cells and presently prepares regulatory submission for clinical investigations. About Avirmax Biopharma Inc. Avirmax Biopharma Inc. is a San Francisco-based company specializing in developing rAAV-mediated therapeutics for ocular diseases using its AAV engineering technologies and Sf9-based AAV manufacturing platform. Since its inception, Avirmax Biopharma has been dedicated to developing safe, effective, affordable, and accessible AAV gene therapy products for the unmet needs of patients. Visit us at avirmax.com for more information. Contact Please contact June Song, Associate Director of Operations Email: [email protected] Tel: +1-510-641-0201 Address 25503 Whitesell Street Hayward, CA 94545 USA SOURCE Avirmax

The observations from associational studies, however, raise a very disturbing possibility. Suppose a well-executed RCT showed that regular, low-level aspirin use was to some degree protective against breast cancer? The pro-Tylenol, anti-ASA campaign must surely have significantly reduced the consumption of aspirin over the decades. Has this, then, contributed materially to the incidence of breast cancer? All the more reason for doing the trial, and doing it soon. While we are waiting for Godot, however, why not advise (hello, CCS) those of the female persuasion to take a couple of aspirins? You are unlikely to do harm, and you might save a few lives. From: Language: English | French “Frankly, My Dear, I Don't Give a Damn” Robert G. Evans, PhD Healthc Policy. 2014; 10(2): 10–18.  PMCID: PMC4748353 PMID: 25617511 www.ascurin.com Author information Copyright and License information PMC Disclaimer

Great news from Race Oncology CEO and I am very proud to say that I have shares in the company. https://raceoncology.com/ I am pleased to share with you results of preclinical work that has found Bisantrene, as a single agent treatment, to be effective against human multiple myeloma in a mouse model and more effective in combination with the standard of care multiple myeloma proteasome inhibitor, carfilzomib. In this study, treatment with Bisantrene was found to significantly slow multiple myeloma disease progression, whereas carfilzomib at the maximum tolerated dosage showed no single-agent activity. However, despite a lack of activity when used alone, carfilzomib, when combined with Bisantrene, was able to slow disease progression more than Bisantrene treatment alone.  It is exciting to see the potential clinical utility of Bisantrene grow. Carfilzomib is a highly active treatment for multiple myeloma, but it comes with very serious cardiotoxicity risks. The potential for using bisantrene to not only better treat multiple myeloma, but also protect patients from the heart damage caused by carfilzomib, is worthy of further investigation. Next steps now include completing mouse models of carfilzomib-induced cardiotoxicity to confirm the cardioprotective properties of bisantrene in vivo, and then exploring options for clinical studies evaluating bisantrene in combination with carfilzomib as a more effective and cardio-safer treatment for patients with multiple myeloma. For further details please visit our Investor Hub here. Best regards, Dr Daniel Tillett  Chief Executive Officer

A unique opportunity for Early and Mid Career Researchers #EMCR to present their work at the #ProCan 2024 Sydney International Conference: Advancing Multi-omics into the Clinic. The abstract deadline is the 9th of September, 2024. This will be a two-day international conference in Sydney where distinguished international speakers will discuss challenges and opportunities for integrating multi-omics into #cancer management regarding biomarker and drug discovery. Bioinformatics and challenges in multi-omic integration will be discussed in a dedicated session #Bioinformatics. There will also be a dedicated session to discuss challenges in regulatory approval #TGA, #HTA, impact on early phase #clinicaltrials, intellectual property (IP) and market access. #cancerresearch, #proteomics, #genomics, #cancer, #oncology, #biomarker, #drugdiscovery. Looking forward to seeing you all: https://lnkd.in/dstS8Gyx Children's Medical Research Institute, University of Sydney, UNSW, The Westmead Institute for Medical Research, Ingham Institute Medical Physics, Children's Cancer Institute, Victorian Clinical Genetics Services (VCGS), University of Adelaide, SAHMRI, Garvan Institute of Medical Research, Omico, Westmead Research Hub

Refine your clinical decisions with actionable insights derived from real-world data. Our upcoming webinar on advanced bladder cancer will show you how. Free registrations for HCPs: https://lnkd.in/eQz-8Dwa

How to strike the right balance between longevity and living well with advanced bladder cancer? Join us in our next webinar to refine patient-caregiver communication and optimize treatment choices: https://lnkd.in/eQz-8Dwa #BladderCancerCare #BladderCancer

Great news from Race Oncology CEO and I am very proud to say that I have shares in the company. https://raceoncology.com/ I am pleased to share with you results of preclinical work that has found Bisantrene, as a single agent treatment, to be effective against human multiple myeloma in a mouse model and more effective in combination with the standard of care multiple myeloma proteasome inhibitor, carfilzomib. In this study, treatment with Bisantrene was found to significantly slow multiple myeloma disease progression, whereas carfilzomib at the maximum tolerated dosage showed no single-agent activity. However, despite a lack of activity when used alone, carfilzomib, when combined with Bisantrene, was able to slow disease progression more than Bisantrene treatment alone.  It is exciting to see the potential clinical utility of Bisantrene grow. Carfilzomib is a highly active treatment for multiple myeloma, but it comes with very serious cardiotoxicity risks. The potential for using bisantrene to not only better treat multiple myeloma, but also protect patients from the heart damage caused by carfilzomib, is worthy of further investigation. Next steps now include completing mouse models of carfilzomib-induced cardiotoxicity to confirm the cardioprotective properties of bisantrene in vivo, and then exploring options for clinical studies evaluating bisantrene in combination with carfilzomib as a more effective and cardio-safer treatment for patients with multiple myeloma. For further details please visit our Investor Hub here. Best regards, Dr Daniel Tillett  Chief Executive Officer